salicylates and Budd-Chiari-Syndrome

Transjugular intrahepatic portosystemic shunt (TIPS) is nowadays the benchmark treatment of severe portal hypertension complications. However, besides usual contraindication to the procedure (namely recurrent hepatic encephalopathy, severe liver dysfunction, right heart failure and/or pulmonary hypertension), TIPS appears regularly unfeasible due to abnormal and/or distorted anatomy. In this situation, the only non-surgical approaches to treat severe portal hypertension consist in the creation of an intrahepatic portocaval shunt from percutaneous (direct intrahepatic portocaval shunt - DIPS) or transjugular route (transjugular transcaval intrahepatic portosystemic shunt - TTIPS). These procedures have been rapidly adopted in patients with Budd-Chiari syndrome but are only poorly reported in patients with cirrhosis and without BCS. Considering the broadening landscape of TIPS indication in patients with cirrhosis within the last ten years, we aimed to describe the techniques, safety and efficacy of DIPS and TTIPS procedures as an alternative to TIPS in case of unfavourable anatomy.

Topics: Budd-Chiari Syndrome; Humans; Hypertension, Portal; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Salicylates; Treatment Outcome

Topics: Budd-Chiari Syndrome; Endovascular Procedures; Humans; Portasystemic Shunt, Transjugular Intrahepatic; Retrospective Studies; Salicylates; Treatment Outcome